Published :
Tables : 552
Figures : 47
Category : Healthcare
No. of Pages : 233
Report Code : HC-U4723
Viral Vectors and Plasmid DNA Manufacturing Market is poised to value over CAGR of over 18.8% during the forecast period 2022 to 2028. FutureWise Market Research has instantiated a report that provides an intricate analysis of Viral Vectors and Plasmid DNA Manufacturing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Viral Vectors and Plasmid DNA Manufacturing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Viral Vectors and Plasmid DNA Manufacturing Market: • Merck KGaA • Lonza • FUJIFILM Diosynth Biotechnologies U.S.A., Inc. • Cobra Biologics Ltd. • Brammer Bio • Waisman Biomanufacturing • Genezen • YPOSKESI • Advanced BioScience Laboratories, Inc. (ABL, Inc.) • Novasep Holding S.A.S • ATVIO Biotech Ltd • Vigene Biosciences, Inc. • General Electric Company (GE Healthcare) • CEVEC Pharmaceuticals GmbH • Batavia Biosciences B.V. • Biovian Oy • Wuxi AppTec Co., Ltd. • VGXI, Inc • Paragon Bioservices, Inc • Miltenyi Biotec GmbH • SIRION Biotech GmbH • Virovek Incorporation • BioNTech IMFS GmbH • VIVEbiotech S.L. • Creative Biogene • Vibalogics GmbH (Note: The list of the major players will be updated with the latest market scenario and trends) Viral Vectors and Plasmid DNA Manufacturing Market Segmentation: By Vector Type • Adenovirus • Retrovirus • Plasmid DNA • AAV • Lentivirus • Others By Workflow • Upstream Processing o Vector Amplification & Expansion o Vector Recovery/Harvesting • Downstream Processing o Purification o Fill-finish By Application • Antisense & RNAi • Gene Therapy • Cell Therapy • Vaccinology By Disease • Cancer • Genetic Disorders • Infectious Diseases • Others By End-use • Pharmaceutical and Biopharmaceutical Companies • Research Institutes By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, By Workflow, By Application, By Disease, By End-use and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
FutureWise Market Research has instantiated a report that provides an intricate analysis of Viral Vectors and Plasmid DNA Manufacturing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Viral Vectors and Plasmid DNA Manufacturing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the Viral Vectors and Plasmid DNA Manufacturing Market: • Merck KGaA • Lonza • FUJIFILM Diosynth Biotechnologies U.S.A., Inc. • Cobra Biologics Ltd. • Brammer Bio • Waisman Biomanufacturing • Genezen • YPOSKESI • Advanced BioScience Laboratories, Inc. (ABL, Inc.) • Novasep Holding S.A.S • ATVIO Biotech Ltd • Vigene Biosciences, Inc. • General Electric Company (GE Healthcare) • CEVEC Pharmaceuticals GmbH • Batavia Biosciences B.V. • Biovian Oy • Wuxi AppTec Co., Ltd. • VGXI, Inc • Paragon Bioservices, Inc • Miltenyi Biotec GmbH • SIRION Biotech GmbH • Virovek Incorporation • BioNTech IMFS GmbH • VIVEbiotech S.L. • Creative Biogene • Vibalogics GmbH (Note: The list of the major players will be updated with the latest market scenario and trends)
Viral Vectors and Plasmid DNA Manufacturing Market Segmentation: By Vector Type • Adenovirus • Retrovirus • Plasmid DNA • AAV • Lentivirus • Others By Workflow • Upstream Processing o Vector Amplification & Expansion o Vector Recovery/Harvesting • Downstream Processing o Purification o Fill-finish By Application • Antisense & RNAi • Gene Therapy • Cell Therapy • Vaccinology By Disease • Cancer • Genetic Disorders • Infectious Diseases • Others By End-use • Pharmaceutical and Biopharmaceutical Companies • Research Institutes By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, By Workflow, By Application, By Disease, By End-use and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Viral Vectors and Plasmid DNA Manufacturing Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Viral Vectors and Plasmid DNA Manufacturing Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Viral Vectors and Plasmid DNA Manufacturing Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Adenovirus 7.2. Retrovirus 7.3. Plasmid DNA 7.4. AAV 7.5. Lentivirus 7.6. Others 8. Global Viral Vectors and Plasmid DNA Manufacturing Market, by Workflow Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Upstream Processing 8.1.1. Vector Amplification & Expansion 8.1.2. Vector Recovery/Harvesting 8.2. Downstream Processing 8.2.1. Purification 8.2.2. Fill-finish 9. Global Viral Vectors and Plasmid DNA Manufacturing Market, by Application Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Antisense & RNAi 9.2. Gene Therapy 9.3. Cell Therapy 9.4. Vaccinology 10. Global Viral Vectors and Plasmid DNA Manufacturing Market, by Disease Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Cancer 10.2. Genetic Disorders 10.3. Infectious Diseases 10.4. Others 11. Global Viral Vectors and Plasmid DNA Manufacturing Market, by End-use Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Pharmaceutical and Biopharmaceutical Companies 11.2. Research Institutes 12. North America Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028 13. Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028 14. Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Rest of Europe 14.3. Market Size (USD Million) Forecast for Europe 2022-2028 15. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. India 15.2.4. Australia and New Zealand 15.2.5. ASEAN 15.2.6. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 16. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028 17. Market Share Analysis and Competitive Landscape 17.1. Global Landscape - Key Players, Revenue and Presence 17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 17.3. Global Emerging Companies 17.4. North America - Market Share Analysis and Key Regional Players 17.5. Europe - Market Share Analysis and Key Regional Players 17.6. Asia Pacific - Market Share Analysis and Key Regional Players 17.7. Global Key Player - Growth Matrix 18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 18.1. Merck KGaA 18.1.1. Company Overview 18.1.2. Product Portfolio 18.1.3. SWOT Analysis 18.1.4. Financial Overview 18.1.5. Strategic Overview 18.2. Lonza 18.2.1. Company Overview 18.2.2. Product Portfolio 18.2.3. SWOT Analysis 18.2.4. Financial Overview 18.2.5. Strategic Overview 18.3. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. 18.3.1. Company Overview 18.3.2. Product Portfolio 18.3.3. SWOT Analysis 18.3.4. Financial Overview 18.3.5. Strategic Overview 18.4. Cobra Biologics Ltd. 18.4.1. Company Overview 18.4.2. Product Portfolio 18.4.3. SWOT Analysis 18.4.4. Financial Overview 18.4.5. Strategic Overview 18.5 Brammer Bio 18.5.1. Company Overview 18.5.2. Product Portfolio 18.5.3. SWOT Analysis 18.5.4. Financial Overview 18.5.5. Strategic Overview 18.6 Waisman Biomanufacturing 18.6.1. Company Overview 18.6.2. Product Portfolio 18.6.3. SWOT Analysis 18.6.4. Financial Overview 18.6.5. Strategic Overview 18.7. Genezen 18.7.1. Company Overview 18.7.2. Product Portfolio 18.7.3. SWOT Analysis 18.7.4. Financial Overview 18.7.5. Strategic Overview 18.8. YPOSKESI 18.8.1. Company Overview 18.8.2. Product Portfolio 18.8.3. SWOT Analysis 18.8.4. Financial Overview 18.8.5. Strategic Overview 18.9. Advanced BioScience Laboratories, Inc. (ABL, Inc.) 18.9.1. Company Overview 18.9.2. Product Portfolio 18.9.3. SWOT Analysis 18.9.4. Financial Overview 18.9.5. Strategic Overview 18.10.Novasep Holding S.A.S 18.10.1. Company Overview 18.10.2. Product Portfolio 18.10.3. SWOT Analysis 18.10.4. Financial Overview 18.10.5. Strategic Overview 18.11.ATVIO Biotech Ltd. 18.11.1. Company Overview 18.11.2. Product Portfolio 18.11.3. SWOT Analysis 18.11.4. Financial Overview 18.11.5. Strategic Overview 18.12.Vigene Biosciences, Inc. 18.12.1. Company Overview 18.12.2. Product Portfolio 18.12.3. SWOT Analysis 18.12.4. Financial Overview 18.12.5. Strategic Overview 18.13.General Electric Company (GE Healthcare) 18.13.1. Company Overview 18.13.2. Product Portfolio 18.13.3. SWOT Analysis 18.13.4. Financial Overview 18.13.5. Strategic Overview 18.14.CEVEC Pharmaceuticals GmbH 18.14.1. Company Overview 18.14.2. Product Portfolio 18.14.3. SWOT Analysis 18.14.4. Financial Overview 18.14.5. Strategic Overview 18.15.Batavia Biosciences B.V. 18.15.1. Company Overview 18.15.2. Product Portfolio 18.15.3. SWOT Analysis 18.15.4. Financial Overview 18.15.5. Strategic Overview 18.16.Biovian Oy 18.16.1. Company Overview 18.16.2. Product Portfolio 18.16.3. SWOT Analysis 18.16.4. Financial Overview 18.16.5. Strategic Overview 18.17.Wuxi AppTec Co., Ltd. 18.17.1. Company Overview 18.17.2. Product Portfolio 18.17.3. SWOT Analysis 18.17.4. Financial Overview 18.17.5. Strategic Overview 18.18.VGXI, Inc. 18.18.1. Company Overview 18.18.2. Product Portfolio 18.18.3. SWOT Analysis 18.18.4. Financial Overview 18.18.5. Strategic Overview 18.19.Paragon Bioservices, Inc. 18.19.1. Company Overview 18.19.2. Product Portfolio 18.19.3. SWOT Analysis 18.19.4. Financial Overview 18.19.5. Strategic Overview 18.20.Miltenyi Biotec GmbH 18.20.1. Company Overview 18.20.2. Product Portfolio 18.20.3. SWOT Analysis 18.20.4. Financial Overview 18.20.5. Strategic Overview 18.21.SIRION Biotech GmbH 18.21.1. Company Overview 18.21.2. Product Portfolio 18.21.3. SWOT Analysis 18.21.4. Financial Overview 18.21.5. Strategic Overview 18.22.Virovek Incorporation 18.22.1. Company Overview 18.22.2. Product Portfolio 18.22.3. SWOT Analysis 18.22.4. Financial Overview 18.22.5. Strategic Overview 18.23.BioNTech IMFS GmbH 18.23.1. Company Overview 18.23.2. Product Portfolio 18.23.3. SWOT Analysis 18.23.4. Financial Overview 18.23.5. Strategic Overview 18.24.VIVEbiotech S.L. 18.24.1. Company Overview 18.24.2. Product Portfolio 18.24.3. SWOT Analysis 18.24.4. Financial Overview 18.24.5. Strategic Overview 18.25.Creative Biogene 18.25.1. Company Overview 18.25.2. Product Portfolio 18.25.3. SWOT Analysis 18.25.4. Financial Overview 18.25.5. Strategic Overview 18.26.Vibalogics GmbH 18.26.1. Company Overview 18.26.2. Product Portfolio 18.26.3. SWOT Analysis 18.26.4. Financial Overview 18.26.5. Strategic Overview 19. Pre and Post COVID-19 Impact 19.1. Positive influence on the healthcare industry 19.2. The financial disruption of the manufacturing sector 19.3. Impact of COVID-19 on emerging companies 19.4. Significant mandates in the healthcare regulations initiated by administrations 19.5. The overall economic slowdown of the developing and developed nations 20. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders
2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study
3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights
4. Global Viral Vectors and Plasmid DNA Manufacturing Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Viral Vectors and Plasmid DNA Manufacturing Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Viral Vectors and Plasmid DNA Manufacturing Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Adenovirus 7.2. Retrovirus 7.3. Plasmid DNA 7.4. AAV 7.5. Lentivirus 7.6. Others
8. Global Viral Vectors and Plasmid DNA Manufacturing Market, by Workflow Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Upstream Processing 8.1.1. Vector Amplification & Expansion 8.1.2. Vector Recovery/Harvesting 8.2. Downstream Processing 8.2.1. Purification 8.2.2. Fill-finish
9. Global Viral Vectors and Plasmid DNA Manufacturing Market, by Application Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Antisense & RNAi 9.2. Gene Therapy 9.3. Cell Therapy 9.4. Vaccinology
10. Global Viral Vectors and Plasmid DNA Manufacturing Market, by Disease Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Cancer 10.2. Genetic Disorders 10.3. Infectious Diseases 10.4. Others
11. Global Viral Vectors and Plasmid DNA Manufacturing Market, by End-use Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Pharmaceutical and Biopharmaceutical Companies 11.2. Research Institutes
12. North America Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028
13. Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028
14. Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Rest of Europe 14.3. Market Size (USD Million) Forecast for Europe 2022-2028
15. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. India 15.2.4. Australia and New Zealand 15.2.5. ASEAN 15.2.6. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
16. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028
17. Market Share Analysis and Competitive Landscape 17.1. Global Landscape - Key Players, Revenue and Presence 17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 17.3. Global Emerging Companies 17.4. North America - Market Share Analysis and Key Regional Players 17.5. Europe - Market Share Analysis and Key Regional Players 17.6. Asia Pacific - Market Share Analysis and Key Regional Players 17.7. Global Key Player - Growth Matrix
18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 18.1. Merck KGaA 18.1.1. Company Overview 18.1.2. Product Portfolio 18.1.3. SWOT Analysis 18.1.4. Financial Overview 18.1.5. Strategic Overview 18.2. Lonza 18.2.1. Company Overview 18.2.2. Product Portfolio 18.2.3. SWOT Analysis 18.2.4. Financial Overview 18.2.5. Strategic Overview 18.3. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. 18.3.1. Company Overview 18.3.2. Product Portfolio 18.3.3. SWOT Analysis 18.3.4. Financial Overview 18.3.5. Strategic Overview 18.4. Cobra Biologics Ltd. 18.4.1. Company Overview 18.4.2. Product Portfolio 18.4.3. SWOT Analysis 18.4.4. Financial Overview 18.4.5. Strategic Overview 18.5 Brammer Bio 18.5.1. Company Overview 18.5.2. Product Portfolio 18.5.3. SWOT Analysis 18.5.4. Financial Overview 18.5.5. Strategic Overview 18.6 Waisman Biomanufacturing 18.6.1. Company Overview 18.6.2. Product Portfolio 18.6.3. SWOT Analysis 18.6.4. Financial Overview 18.6.5. Strategic Overview 18.7. Genezen 18.7.1. Company Overview 18.7.2. Product Portfolio 18.7.3. SWOT Analysis 18.7.4. Financial Overview 18.7.5. Strategic Overview 18.8. YPOSKESI 18.8.1. Company Overview 18.8.2. Product Portfolio 18.8.3. SWOT Analysis 18.8.4. Financial Overview 18.8.5. Strategic Overview 18.9. Advanced BioScience Laboratories, Inc. (ABL, Inc.) 18.9.1. Company Overview 18.9.2. Product Portfolio 18.9.3. SWOT Analysis 18.9.4. Financial Overview 18.9.5. Strategic Overview 18.10.Novasep Holding S.A.S 18.10.1. Company Overview 18.10.2. Product Portfolio 18.10.3. SWOT Analysis 18.10.4. Financial Overview 18.10.5. Strategic Overview 18.11.ATVIO Biotech Ltd. 18.11.1. Company Overview 18.11.2. Product Portfolio 18.11.3. SWOT Analysis 18.11.4. Financial Overview 18.11.5. Strategic Overview 18.12.Vigene Biosciences, Inc. 18.12.1. Company Overview 18.12.2. Product Portfolio 18.12.3. SWOT Analysis 18.12.4. Financial Overview 18.12.5. Strategic Overview 18.13.General Electric Company (GE Healthcare) 18.13.1. Company Overview 18.13.2. Product Portfolio 18.13.3. SWOT Analysis 18.13.4. Financial Overview 18.13.5. Strategic Overview 18.14.CEVEC Pharmaceuticals GmbH 18.14.1. Company Overview 18.14.2. Product Portfolio 18.14.3. SWOT Analysis 18.14.4. Financial Overview 18.14.5. Strategic Overview 18.15.Batavia Biosciences B.V. 18.15.1. Company Overview 18.15.2. Product Portfolio 18.15.3. SWOT Analysis 18.15.4. Financial Overview 18.15.5. Strategic Overview 18.16.Biovian Oy 18.16.1. Company Overview 18.16.2. Product Portfolio 18.16.3. SWOT Analysis 18.16.4. Financial Overview 18.16.5. Strategic Overview 18.17.Wuxi AppTec Co., Ltd. 18.17.1. Company Overview 18.17.2. Product Portfolio 18.17.3. SWOT Analysis 18.17.4. Financial Overview 18.17.5. Strategic Overview 18.18.VGXI, Inc. 18.18.1. Company Overview 18.18.2. Product Portfolio 18.18.3. SWOT Analysis 18.18.4. Financial Overview 18.18.5. Strategic Overview 18.19.Paragon Bioservices, Inc. 18.19.1. Company Overview 18.19.2. Product Portfolio 18.19.3. SWOT Analysis 18.19.4. Financial Overview 18.19.5. Strategic Overview 18.20.Miltenyi Biotec GmbH 18.20.1. Company Overview 18.20.2. Product Portfolio 18.20.3. SWOT Analysis 18.20.4. Financial Overview 18.20.5. Strategic Overview 18.21.SIRION Biotech GmbH 18.21.1. Company Overview 18.21.2. Product Portfolio 18.21.3. SWOT Analysis 18.21.4. Financial Overview 18.21.5. Strategic Overview 18.22.Virovek Incorporation 18.22.1. Company Overview 18.22.2. Product Portfolio 18.22.3. SWOT Analysis 18.22.4. Financial Overview 18.22.5. Strategic Overview 18.23.BioNTech IMFS GmbH 18.23.1. Company Overview 18.23.2. Product Portfolio 18.23.3. SWOT Analysis 18.23.4. Financial Overview 18.23.5. Strategic Overview 18.24.VIVEbiotech S.L. 18.24.1. Company Overview 18.24.2. Product Portfolio 18.24.3. SWOT Analysis 18.24.4. Financial Overview 18.24.5. Strategic Overview 18.25.Creative Biogene 18.25.1. Company Overview 18.25.2. Product Portfolio 18.25.3. SWOT Analysis 18.25.4. Financial Overview 18.25.5. Strategic Overview 18.26.Vibalogics GmbH 18.26.1. Company Overview 18.26.2. Product Portfolio 18.26.3. SWOT Analysis 18.26.4. Financial Overview 18.26.5. Strategic Overview
19. Pre and Post COVID-19 Impact 19.1. Positive influence on the healthcare industry 19.2. The financial disruption of the manufacturing sector 19.3. Impact of COVID-19 on emerging companies 19.4. Significant mandates in the healthcare regulations initiated by administrations 19.5. The overall economic slowdown of the developing and developed nations
20. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics